1
|
Batista RL, Mendonca BB. The Molecular Basis of 5α-Reductase Type 2 Deficiency. Sex Dev 2022; 16:171-183. [PMID: 35793650 DOI: 10.1159/000525119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 05/13/2022] [Indexed: 11/19/2022] Open
Abstract
The 5α-reductase type 2 enzyme catalyzes the conversion of testosterone into dihydrotestosterone, playing a crucial role in male development. This enzyme is encoded by the SRD5A2 gene, which maps to chromosome 2 (2p23), consists of 5 exons and 4 introns, and encodes a 254 amino acid protein. Disruptions in this gene are the molecular etiology of a subgroup of differences of sex development (DSD) in 46,XY patients. Affected individuals present a large range of external genitalia undervirilization, ranging from almost typically female external genitalia to predominantly typically male external genitalia with minimal undervirilization, including isolated micropenis. This is an updated review of the implication of the SRD5A2 gene in 5α-reductase type 2 enzyme deficiency. For that, we identified 451 cases from 48 countries of this particular 46,XY DSD from the literature with reported variants in the SRD5A2 gene. Herein, we present the SRD5A2 mutational profile, the SRD5A2 polymorphisms, and the functional studies related to SRD5A2 variants to detail the molecular etiology of this condition.
Collapse
Affiliation(s)
- Rafael L Batista
- Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Disciplina de Endocrinologia, do Departamento de Clínica Médica, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.,Endocrine Oncology Unit, Instituto do Câncer do Estado de São Paulo, ICESP, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Berenice B Mendonca
- Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Disciplina de Endocrinologia, do Departamento de Clínica Médica, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| |
Collapse
|
2
|
Ruetten H, Vezina CM. Relevance of dog as an animal model for urologic diseases. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2022; 189:35-65. [PMID: 35595352 DOI: 10.1016/bs.pmbts.2021.12.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We utilize animal models in urologic research to improve understanding of urinary physiology, determine the etiology of many urologic diseases, and discover and test novel therapeutic interventions. Dogs have a similar urinary tract anatomy and physiology to human and they develop many urologic diseases spontaneously. This chapter offers detailed comparisons of urinary tract anatomy, physiology, and the most common urologic diseases between humans and dogs. Dogs offer a unique opportunity for urologic research because they can be studied in research colonies and in client owned cohorts. Dogs also are among a limited number of non-human species that require continence and socially appropriate urinary behaviors (ex. going to the bathroom outside, training to not have submissive urination, etc.). These features make dogs unique in the animal kingdom and make them an ideal animal model for urologic research.
Collapse
Affiliation(s)
- Hannah Ruetten
- Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, United States
| | - Chad M Vezina
- Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, United States.
| |
Collapse
|
3
|
Batista RL, Mendonca BB. Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide. APPLICATION OF CLINICAL GENETICS 2020; 13:83-96. [PMID: 32346305 PMCID: PMC7167369 DOI: 10.2147/tacg.s198178] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 02/20/2020] [Indexed: 12/12/2022]
Abstract
Introduction The conversion of testosterone into dihydrotestosterone is catalyzed by the 5α-reductase type 2 enzyme which plays a crucial role in the external genitalia virilization. It is encoded by the SRD5A2 gene. Allelic variants in this gene cause a 46,XY DSD with no genotype-phenotype relationship. It was firstly reported in the early 70s from isolated clusters. Since then, several cases have been reported. Putting together, it will expand the knowledge on the molecular bases of androgen milieu. Methods We searched for SRD5A2 allelic variants (AV) in the literature (PubMed, Embase, MEDLINE) and websites (ensembl, HGMD, ClinVar). Only cases with AV in both alleles, either in homozygous or compound heterozygous were included. The included cases were analyzed according to ethnicity, exon, domain, aminoacid (aa) conservation, age at diagnosis, sex assignment, gender reassignment, external genitalia virilization and functional studies. External genitalia virilization was scored using Sinnecker scale. Conservation analysis was carried out using the CONSURF platform. For categorical variables, we used X2 test and Cramer's V. Continuous variables were analyzed by t test or ANOVA. Concordance was estimated by Kappa. Results We identified 434 cases of 5ARD2 deficiencies from 44 countries. Most came from Turkey (23%), China (17%), Italy (9%), and Brazil (7%). Sixty-nine percent were assigned as female. There were 70% of homozygous allelic variants and 30% compound heterozygous. Most were missense variants (76%). However, small indels (11%), splicing (5%) and large deletions (4%) were all reported. They were distributed along with all exons with exon 1 (33%) and exon 4 (25%) predominance. Allelic variants in the exon 4 (NADPH-binding domain) resulted in lower virilization (p<0.0001). The codons 55, 65, 196, 235 and 246 are hotspots making up 25% of all allelic variants. Most of them (76%) were located at conserved aa. However, allelic variants at non-conserved aa were more frequently indels (28% vs 6%; p<0.01). The overall rate of gender change from female to male ranged from 16% to 70%. The lowest rate of gender change from female to male occurred in Turkey and the highest in Brazil. External genitalia virilization was similar between those who changed and those who kept their assigned gender. The gender change rate was significantly different across the countries (V=0.44; p<0.001) even with similar virilization scores. Conclusion 5ARD2 deficiency has a worldwide distribution. Allelic variants at the NADPH-ligand region cause lower virilization. Genitalia virilization influenced sex assignment but not gender change which was influenced by cultural aspects across the countries. Molecular diagnosis influenced on sex assignment, favoring male sex assignment in newborns with 5α-reductase type 2 deficiency.
Collapse
Affiliation(s)
- Rafael Loch Batista
- Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Disciplina de Endocrinologia, do Departamento de Clínica Médica, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Berenice Bilharinho Mendonca
- Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular/LIM42, Hospital das Clínicas, Disciplina de Endocrinologia, do Departamento de Clínica Médica, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| |
Collapse
|
4
|
Yeap BB, Knuiman MW, Handelsman DJ, Ho KKY, Hui J, Divitini ML, Arscott GM, McQuillan B, Hung J, Beilby JP. A 5α-reductase (SRD5A2) polymorphism is associated with serum testosterone and sex hormone-binding globulin in men, while aromatase (CYP19A1) polymorphisms are associated with oestradiol and luteinizing hormone reciprocally. Clin Endocrinol (Oxf) 2019; 90:301-311. [PMID: 30353958 DOI: 10.1111/cen.13885] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Revised: 10/09/2018] [Accepted: 10/18/2018] [Indexed: 01/04/2023]
Abstract
CONTEXT Pituitary luteinizing hormone (LH) stimulates testicular production of testosterone (T) which is metabolized to dihydrotestosterone (DHT) by 5α-reductase and to oestradiol (E2) by aromatase. How the activity of population variants in these enzymes impacts on gonadal function is unclear. We examined whether polymorphisms in 5α-reductase (SRD5A2) and aromatase (CYP19A1) genes predict circulating sex hormone concentrations. DESIGN Cross-sectional analysis of 1865 community-dwelling men aged 50.4 ± 16.8 years. MEASUREMENTS Early morning sera assayed for T, DHT and E2 (mass spectrometry), and SHBG and LH (immunoassay). Two SRD5A2 and eleven CYP19A1 polymorphisms were analysed by PCR. Regression models were adjusted for age and cardiometabolic risk factors. RESULTS SRD5A2 polymorphism rs9282858 GA vs. GG was associated with higher serum T (+1.5 nmol/L, P < 0.001) and higher SHBG (+3.3 nmol/L, P = 0.001). CYP19A1 polymorphisms were associated with higher serum E2 and lower LH in reciprocal fashion, from which the two-copy haplotype rs10046 = T/rs2899470 = G/rs11575899 = I/rs700518 = G/rs17703883 = T was associated with higher E2 (63.4 vs. 56.5 pmol/L, P = 0.001) and lower LH (3.9 vs. 4.5 IU/L, P = 0.001) compared to null copies. Conversely, rs10046 = C/rs2899470 = T/rs11575899 = D/rs700518 = A/rs17703883 = C was associated with lower E2 (51.8 vs. 62.0 pmol/L, P = 0.001) and higher LH (5.7 vs. 3.9 IU/L, P < 0.001). These haplotypes were associated primarily with differences in E2 in men <65 years and LH in men ≥65 years. CONCLUSIONS A 5α-reductase polymorphism predicts circulating T and SHBG, while aromatase polymorphisms predict E2 and LH in reciprocal fashion. Age and aromatase polymorphisms interact to affect E2 and LH. How these functional polymorphisms impact on male reproductive and general health outcomes requires further study.
Collapse
Affiliation(s)
- Bu B Yeap
- Medical School, University of Western Australia, Perth, Western Australia, Australia
- Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western Australia, Australia
| | - Matthew W Knuiman
- School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia
| | - David J Handelsman
- ANZAC Research Institute, University of Sydney, Sydney, New South Wales, Australia
| | - Ken K Y Ho
- Garvan Institute of Medical Research, Sydney, New South Wales, Australia
| | - Jennie Hui
- PathWest Laboratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
| | - Mark L Divitini
- School of Population and Global Health, University of Western Australia, Perth, Western Australia, Australia
| | - Gillian M Arscott
- PathWest Laboratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
| | - Brendan McQuillan
- Medical School, University of Western Australia, Perth, Western Australia, Australia
- Department of Cardiovascular Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
| | - Joseph Hung
- Medical School, University of Western Australia, Perth, Western Australia, Australia
- Department of Cardiovascular Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
| | - John P Beilby
- PathWest Laboratory Medicine, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
| |
Collapse
|
5
|
Fang C, Guo ZQ, Chen XY, Liu TZ, Zeng XT, Wang XH. Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer: A meta-analysis based on 20 publications. Medicine (Baltimore) 2017; 96:e6791. [PMID: 28489754 PMCID: PMC5428588 DOI: 10.1097/md.0000000000006791] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The pathogenetic mechanism of prostate cancer (PCa) has not been understood completely, and gene polymorphisms have been demonstrated to play a critical role in the course. It has been reported that rs9282858 polymorphism of steroid 5-α-reductase type 2 (SRD5A2) may affect the susceptibility of PCa, but some researches showed different results. We therefore carried out a meta-analysis to clarify this relationship.Relevant studies were identified through PubMed and Chinese National Knowledge Infrastructure databases concerning the association between SRD5A2 rs9282858 polymorphism and PCa. Odds ratios (ORs) with their 95% confidence intervals (95% CIs) were calculated to assess the strength of the association. Additionally, stratified analyses were performed based on ethnicity and source of control. Besides, heterogeneity test, sensitivity analysis, and publication bias evaluation were conducted in current meta-analysis as well.Ultimately, 20 publications incorporating 30 case-control studies were included in this meta-analysis, involving a total of 7300 cases and 7952 controls. The overall results demonstrated that SRD5A2 rs9282858 polymorphism was remarkably associated with increased susceptibility of PCa (TT vs. AA: OR = 4.08, 95% CI = 1.94-8.58; TT + AT vs. AA: OR = 1.28, 95% CI = 1.11-1.47; TT vs. AA + AT: OR = 4.44, 95% CI = 2.12-9.27; allele T vs. allele A: OR = 1.34, 95% CI = 1.17-1.54). After subgroup analyses by ethnicity and source of control, we also observed a similar trend in Latinos, other-ethnicity, population-based, and hospital-based groups under corresponding genetic models.Our findings indicate that SRD5A2 rs9282858 polymorphism may be a susceptible factor to PCa.
Collapse
Affiliation(s)
- Cheng Fang
- Center for Evidence-Based and Translational Medicine
| | - Zhong-Qiang Guo
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Xiao-Yan Chen
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Tong-Zu Liu
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Xian-Tao Zeng
- Center for Evidence-Based and Translational Medicine
| | - Xing-Huan Wang
- Center for Evidence-Based and Translational Medicine
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| |
Collapse
|
6
|
Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD. Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 2016; 122:2332-40. [PMID: 27164191 PMCID: PMC4956504 DOI: 10.1002/cncr.30071] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Revised: 03/10/2016] [Accepted: 03/14/2016] [Indexed: 11/07/2022]
Abstract
BACKGROUND Prostate cancer is highly influenced by androgens and genes. The authors investigated whether genetic polymorphisms along the androgen biosynthesis and metabolism pathways are associated with androgen concentrations or with the risk of prostate cancer or high-grade disease from finasteride treatment. METHODS A nested case-control study from the Prostate Cancer Prevention Trial using data from men who had biopsy-proven prostate cancer (cases) and a group of biopsy-negative, frequency-matched controls was conducted to investigate the association of 51 single nucleotide polymorphisms (SNPs) in 12 genes of the androgen pathway with overall (total), low-grade, and high-grade prostate cancer incidence and serum hormone concentrations. RESULTS There were significant associations of genetic polymorphisms in steroid 5α-reductase 1 (SRD5A1) (reference SNPs: rs3736316, rs3822430, rs1560149, rs248797, and rs472402) and SRD5A2 (rs2300700) with the risk of high-grade prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial; 2 SNPs were significantly associated with an increased risk (SRD5A1 rs472402 [odds ratio, 1.70; 95% confidence interval, 1.05-2.75; Ptrend = .03] and SRD5A2 rs2300700 [odds ratio, 1.94; 95% confidence interval, 1.19-3.18; Ptrend = .01]). Eleven SNPs in SRD5A1, SRD5A2, cytochrome P450 family 1, subfamily B, polypeptide 1 (CYP1B1), and CYP3A4 were associated with modifying the mean concentrations of serum androgen and sex hormone-binding globulin; and 2 SNPs (SRD5A1 rs824811 and CYP1B1 rs10012; Ptrend < .05) consistently and significantly altered all androgen concentrations. Several SNPs (SRD5A1 rs3822430, SRD5A2 rs2300700, CYP3A43 rs800672, and CYP19 rs700519; Ptrend < .05) were significantly associated with both circulating hormone levels and prostate cancer risk. CONCLUSIONS Germline genetic variations of androgen-related pathway genes are associated with serum androgen concentrations and the risk of prostate cancer. Further studies to examine the functional consequence of novel causal variants are warranted. Cancer 2016;122:2332-2340. © 2016 American Cancer Society.
Collapse
Affiliation(s)
- Douglas K. Price
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | - Cindy H. Chau
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| | - Cathee Till
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Phyllis J. Goodman
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Robin J. Leach
- Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - Teresa L. Johnson-Pais
- Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - Ann W. Hsing
- Cancer Prevention Institute of California, Fremont, CA and Stanford Cancer Institute, Palo Alto, CA
| | - Ashraful Hoque
- Department of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, TX
| | - Howard L. Parnes
- Division of Cancer Prevention, National Cancer Institute, Bethesda, MD
| | - Jeannette M. Schenk
- Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Catherine M. Tangen
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Ian M. Thompson
- Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX
| | - Juergen K.V. Reichardt
- Division of Tropical Health and Medicine, James Cook University, Townsville, QLD, Australia
| | - William D. Figg
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
| |
Collapse
|
7
|
Eren E, Edgünlü T, Asut E, Karakaş Çelik S. Homozygous Ala65Pro Mutation with V89L Polymorphism in SRD5A2 Deficiency. J Clin Res Pediatr Endocrinol 2016; 8:218-23. [PMID: 26761946 PMCID: PMC5096479 DOI: 10.4274/jcrpe.2495] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
OBJECTIVE Deficiency of steroid 5-alpha reductase type 2 (5αRD2) is a rare autosomal recessive disorder caused by mutations in the SRD5A2 gene. A defect in the 5-alpha reductase enzyme, which ensures conversion of testosterone into dihydrotestosterone, leads to disorders of sex development. This study presents the clinical and genetic results of patients with 5αRD2 deficiency. METHODS 5αRD2 deficiency was detected in 6 different patients from 3 unrelated families. All patients were reared as girls. Two of the patients presented with primary amenorrhea, one with primary amenorrhea and rejection of female gender, and the others with masses in their inguinal canals. Chromosome and sex-determining region Y (SRY) gene analyses were performed in all patients. Additionally, five exons of the SRD5A2 gene were amplified with polymerase chain reaction in the obtained DNA samples and evaluated. RESULTS While 46,XY was identified in 5 patients, 47,XXY was detected in one patient. The SRY gene was positive in all patients. The p.Ala65Pro (c193G>C) mutation and V89L polymorphism were observed in exon 1 of the SRD5A2 gene in all patients. CONCLUSION Identification of this mutation and polymorphism is a significant indicator of presence of 5αRD2 deficiency in Southeastern Turkey, a geographical region where consanguineous marriages are also highly common.
Collapse
Affiliation(s)
- Erdal Eren
- Harran University Faculty of Medicine, Department of Pediatric Endocrinology, Şanlıurfa, Turkey; Present position: Uludağ University Faculty of Medicine, Department of Pediatric Endocrinology, Bursa, Turkey, Phone: +90 224 295 05 40 E-mail:
| | - Tuba Edgünlü
- Sıtkı Koçman University Faculty of Health Sciences, Department of Medical Biology, Muğla, Turkey
| | - Emre Asut
- Uludağ University Faculty of Medicine, Department of Pediatrics, Bursa, Turkey
| | - Sevim Karakaş Çelik
- Bülent Ecevit University Faculty of Medicine, Department of Medical Genetics, Zonguldak, Turkey
| |
Collapse
|
8
|
Kachakova D, Mitkova A, Popov E, Beltcheva O, Vlahova A, Dikov T, Christova S, Mitev V, Slavov C, Kaneva R. Polymorphisms in androgen metabolism genes AR, CYP1B1, CYP19, and SRD5A2and prostate cancer risk and aggressiveness in Bulgarian patients. Turk J Med Sci 2016; 46:626-40. [PMID: 27513235 DOI: 10.3906/sag-1501-124] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Accepted: 06/04/2015] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND/AIM The aim of our study was to elucidate the role of polymorphisms in AR, CYP1B1, CYP19, and SRD5A2 genes for prostate cancer (PC) development in Bulgarian patients. MATERIALS AND METHODS We genotyped 246 PC patients and 261 controls (155 with benign prostate hyperplasia and 107 healthy population controls) using direct sequencing, PCR-RFLP, SSCP, and fragment analysis. RESULTS The allele and genotype frequencies of most of the studied variants did not differ significantly between cases and controls. Increased frequencies of the C/C genotype and C allele of rs1056837 in CYP1B1, and genotype 7/8 of the (TTTA)n repeat polymorphism in CYP19, were observed in patients in comparison with controls.The 8/9 and the 7/12 genotypes of (TTTA)n in CYP19 showed suggestive evidence for association with decreased prostate cancer risk and the risk for aggressive disease, respectively. The haplotype analysis revealed 2 CYP1B1 haplotypes associated with PC risk reduction. CONCLUSION Some CYP1B1 haplotypes and genotypes of the CYP19 (TTTA)n repeat appeared to be associated with disease risk or aggressiveness in Bulgarian PC patients. In contrast, the SRD5A2 polymorphisms (V89L and (TA)n repeat), the CAG repeat in AR, and the Arg264Cys variant in CYP19A1 are most likely not implicated in prostate carcinogenesis.
Collapse
Affiliation(s)
- Darina Kachakova
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University of Sofia, Sofia, Bulgaria
| | - Atanaska Mitkova
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University of Sofia, Sofia, Bulgaria
| | - Elenko Popov
- Department of Urology, Medical University of Sofia, Clinic of Urology, Alexandrovska University Hospital, Sofia, Bulgaria
| | - Olga Beltcheva
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University of Sofia, Sofia, Bulgaria
| | - Alexandrina Vlahova
- Department of General and Clinical Pathology, Medical University of Sofia, General and Clinical Pathology Clinic,Alexandrovska University Hospital, Sofia, Bulgaria
| | - Tihomir Dikov
- Department of General and Clinical Pathology, Medical University of Sofia, General and Clinical Pathology Clinic,Alexandrovska University Hospital, Sofia, Bulgaria
| | - Svetlana Christova
- Department of General and Clinical Pathology, Medical University of Sofia, General and Clinical Pathology Clinic,Alexandrovska University Hospital, Sofia, Bulgaria
| | - Vanio Mitev
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University of Sofia, Sofia, Bulgaria
| | - Chavdar Slavov
- Department of Urology, Medical University of Sofia, Clinic of Urology, Alexandrovska University Hospital, Sofia, Bulgaria
| | - Radka Kaneva
- Department of Medical Chemistry and Biochemistry and Molecular Medicine Center, Medical University of Sofia, Sofia, Bulgaria
| |
Collapse
|
9
|
Yeap BB, Knuiman MW, Divitini ML, Hui J, Arscott GM, Handelsman DJ, McLennan SV, Twigg SM, McQuillan B, Hung J, Beilby JP. Epidemiological and Mendelian Randomization Studies of Dihydrotestosterone and Estradiol and Leukocyte Telomere Length in Men. J Clin Endocrinol Metab 2016; 101:1299-306. [PMID: 26789780 DOI: 10.1210/jc.2015-4139] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
CONTEXT Advancing age is accompanied by an accumulation of ill health and shortening of chromosomal telomeres signifying biological aging. T is metabolized to DHT by 5α-reductase (SRD5A2) and to estradiol (E2) by aromatase (CYP19A1). Telomerase preserves telomeres, and T and E2 regulate telomerase expression and activity in vitro. OBJECTIVE The objective of the study was to establish whether circulating T or its metabolites, DHT or E2, and single-nucleotide polymorphisms in SRD5A2 or CYP19A1 associate with leucocyte telomere length (LTL) in men. PARTICIPANTS AND METHODS Early-morning serum T, DHT, and E2 were assayed using mass spectrometry, and SRD5A2 and CYP19A1 single-nucleotide polymorphisms and LTL analyzed by PCR in 980 men from the Western Australian Busselton Health Survey who participated in the study. LTL was expressed as the T/S ratio. RESULTS Men were aged (mean ± SD) 53.7 ± 15.6 years. LTL decreased linearly with age, from the T/S ratio of 1.89 ± 0.41 at younger than 30 years to 1.50 ± 0.49 at 70 to younger than 80 years (r = -0.225, P < .0001). After adjustment for age, DHT and E2 were positively correlated with LTL (DHT, r = 0.069, P = .030; E2, r = 0.068, P = .034). The SRD5A2 rs9282858 polymorphism was associated with serum DHT but not with LTL. Three dominant alleles of CYP19A1 were each associated with lower serum E2 and shorter LTL: rs2899470 T (E2, 59.3 vs 68.6 pmol/L, P < .0001; T/S ratio, 1.54 vs 1.62, P = .045), rs10046 C (60.5 vs 68.1 pmol/L, P = .0005, 1.54 vs 1.62, P = .035), and rs700518 A (59.9 vs 68.9 pmol/L, P < .0001, 1.54 vs 1.63, P = .020). A single-copy haplotype C/T/I/A/T rs10046/rs2899470/rs11575899/rs700518/rs17703883 (52% prevalence) was associated with both lower E2 and shorter LTL. CONCLUSIONS In men, serum DHT and E2 correlate with LTL independently of age. Aromatase gene polymorphisms include three dominant alleles that are associated with both lower serum E2 and shorter LTL. E2 influences telomere length in vivo, thus warranting further studies to examine whether hormonal interventions might slow biological aging in men.
Collapse
Affiliation(s)
- Bu B Yeap
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - Matthew W Knuiman
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - Mark L Divitini
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - Jennie Hui
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - Gillian M Arscott
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - David J Handelsman
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - Susan V McLennan
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - Stephen M Twigg
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - Brendan McQuillan
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - Joseph Hung
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| | - John P Beilby
- School of Medicine and Pharmacology (B.B.Y., B.M., J.Hun.), School of Population Health (M.W.K., M.L.D.), and School of Pathology and Laboratory Medicine (J.P.B.), University of Western Australia, Crawley, Western Australia 6009, Australia; PathWest Laboratory Medicine (J.Hui., G.M.A., J.P.B.) and Department of Cardiovascular Medicine (B.M., J.Hun.), Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; Department of Endocrinology and Diabetes (B.B.Y.), Fiona Stanley Hospital, Murdoch, Western Australia 6150, Australia; ANZAC Research Institute (D.J.H.), Sydney, New South Wales 2138, Australia; and Department Endocrinology (S.V.M., S.M.T.), University of Sydney, Sydney, New South Wales 2006, Australia
| |
Collapse
|
10
|
Moura-Massari VO, Cunha FS, Garcia Gomes L, Bugano Diniz Gomes D, Marcondes JAM, Madureira G, de Mendonca BB, Bachega TASS. The Presence of Clitoromegaly in the Nonclassical Form of 21-Hydroxylase Deficiency Could Be Partially Modulated by the CAG Polymorphic Tract of the Androgen Receptor Gene. PLoS One 2016; 11:e0148548. [PMID: 26848581 PMCID: PMC4744051 DOI: 10.1371/journal.pone.0148548] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Accepted: 01/19/2016] [Indexed: 11/25/2022] Open
Abstract
Background In the nonclassical form (NC), good correlation has been observed between genotypes and 17OH-progesterone (17-OHP) levels. However, this correlation was not identified with regard to the severity of hyperandrogenic manifestations, which could depend on interindividual variability in peripheral androgen sensitivity. Androgen action is modulated by the polymorphic CAG tract (nCAG) of the androgen receptor (AR) gene and by polymorphisms in 5α-reductase type 2 (SRD5A2) enzyme, both of which are involved in the severity of hyperandrogenic disorders. Objectives To analyze whether nCAG-AR and SRD5A2 polymorphisms influence the severity of the nonclassical phenotype. Patients NC patients (n = 114) diagnosed by stimulated-17OHP ≥10 ng/mL were divided into groups according to the beginning of hyperandrogenic manifestations (pediatric and adolescent/adult) and CYP21A2 genotypes (C/C: homozygosis for mild mutations; A/C: compound heterozygosis for severe/mild mutations). Methods CYP21A2 mutations were screened by allelic-specific PCR, MLPA and/or sequencing. HpaII-digested and HpaII-undigested DNA samples underwent GeneScan analysis to study nCAG, and the SRD5A2 polymorphisms were screened by RLFP. Results Mean nCAG did not differ among pediatric, adolescent/adult and asymptomatic subjects. In the C/C genotype, we observed a significantly lower frequency of longer CAG alleles in pediatric patients than in adolescent/adults (p = 0.01). In patients carrying the A/C genotype, the frequencies of shorter and longer CAG alleles did not differ between pediatric patients and adolescent/adults (p>0.05). Patients with clitoromegaly had significantly lower weighted CAG biallelic mean than those without it: 19.1±2.7 and 21.6±2.5, respectively (p = 0.007), independent of the CYP21A2 genotype's severity. The SRD5A2 polymorphisms were not associated with the variability of hyperandrogenic NC phenotypes. Conclusions In this series, we observed a modulatory effect of the CAG-AR tract on clinical manifestations of the NC form. Although the NC form is a monogenic disorder, our preliminary data suggested that the interindividual variability of the hyperandrogenic phenotype could arise from polygenic interactions.
Collapse
Affiliation(s)
- Vivian Oliveira Moura-Massari
- Unidade de Suprarrenal, Laboratório de Hormônios e Genética Molecular LIM 42, Disciplina de Endocrinologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
| | - Flávia Siqueira Cunha
- Unidade de Suprarrenal, Laboratório de Hormônios e Genética Molecular LIM 42, Disciplina de Endocrinologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
- * E-mail: (FSC); (TASSB)
| | - Larissa Garcia Gomes
- Unidade de Suprarrenal, Laboratório de Hormônios e Genética Molecular LIM 42, Disciplina de Endocrinologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
| | - Diogo Bugano Diniz Gomes
- Departamento de Clínica Médica, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
| | - José Antônio Miguel Marcondes
- Unidade de Suprarrenal, Laboratório de Hormônios e Genética Molecular LIM 42, Disciplina de Endocrinologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
| | - Guiomar Madureira
- Unidade de Suprarrenal, Laboratório de Hormônios e Genética Molecular LIM 42, Disciplina de Endocrinologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
| | - Berenice Bilharinho de Mendonca
- Unidade de Suprarrenal, Laboratório de Hormônios e Genética Molecular LIM 42, Disciplina de Endocrinologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
| | - Tânia A. Sartori Sanchez Bachega
- Unidade de Suprarrenal, Laboratório de Hormônios e Genética Molecular LIM 42, Disciplina de Endocrinologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
- * E-mail: (FSC); (TASSB)
| |
Collapse
|
11
|
Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors. Eur J Cancer 2016; 54:104-111. [PMID: 26751392 DOI: 10.1016/j.ejca.2015.11.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Revised: 10/21/2015] [Accepted: 11/05/2015] [Indexed: 12/12/2022]
Abstract
PURPOSE Chemotherapy-treated testicular cancer survivors are at risk for development of the metabolic syndrome, especially in case of decreased androgen levels. Polymorphisms in the gene encoding steroid 5-α-reductase type II (SRD5A2) are involved in altered androgen metabolism. We investigated whether single-nucleotide polymorphisms (SNPs) rs523349 (V89L) and rs9282858 (A49T) in SRD5A2 are associated with cardiometabolic status in testicular cancer survivors. METHODS In 173 chemotherapy-treated testicular cancer survivors, hormone levels and cardiometabolic status were evaluated cross-sectionally (median 5 years [range 3-20] after chemotherapy) and correlated with SNPs in SRD5A2. RESULTS The metabolic syndrome was more prevalent in survivors who were homozygous or heterozygous variant for SRD5A2 rs523349 compared to wild type (33% versus 19%, P = 0.032). In particular, patients with lower testosterone levels (<15 nmol/l) and a variant genotype showed a high prevalence of the metabolic syndrome (66.7%). Mean intima-media thickness of the carotid artery and urinary albumin excretion, both markers of vascular damage, were higher in the group of survivors homozygous or heterozygous variant for rs523349 (0.62 versus 0.57 mm, P = 0.026; 5.6 versus 3.1 mg/24 h, P = 0.017, respectively). No association was found between cardiometabolic status and SNP rs9282858 in SRD5A2. CONCLUSION Metabolic syndrome develops more frequently in testicular cancer survivors homozygous or heterozygous variant for SNP rs523349 in SRD5A2. Altered androgen sensitivity appears to be involved in the development of adverse metabolic and vascular changes in testicular cancer survivors and is a target for intervention.
Collapse
|
12
|
|
13
|
Choi SY, Kim HJ, Cheong HS, Myung SC. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population. Korean J Urol 2015; 56:19-30. [PMID: 25598933 PMCID: PMC4294851 DOI: 10.4111/kju.2015.56.1.19] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Accepted: 11/27/2014] [Indexed: 11/23/2022] Open
Abstract
Purpose Steroid 5-alpha reductase type 2 (SRD5A2) modifies testosterone to dihydrotestosterone (DHT) in the prostate. Single-nucleotide polymorphisms (SNPs) of the SRD5A2 gene might affect DHT. We sought to understand the relationship of SRD5A2 SNPs to prostate cancer in the Korean population. Materials and Methods Twenty-six common SNPs in the SRD5A2 gene were assessed in 272 prostate cancer cases and 173 controls. Single-locus analyses were conducted by using conditional logistic regression. Additionally, we performed a haplotype analysis for the SRD5A2 SNPs tested. Results Among the 20 SNPs and 4 haplotypes, there were no statistically significant results in the prostate cancer patients and the controls. In the logistic analysis of SRD5A2 polymorphisms with prostate-specific antigen (PSA) criteria, two SNPs (rs508562, rs11675297) and haplotype 1 displayed significant results (odds ratio [OR], 1.76; p=0.05; OR, 1.88-2.02; p=0.01-0.04; OR, 0.59; p=0.02, respectively). rs508562, rs11675297, rs2208532, and haplotype 1 (OR, 1.49; p=0.05; OR, 2.02; p=0.05; OR, 2.01; p=0.04; OR, 0.56-0.64, p=0.03-0.04, respectively) had significant associations with Gleason score. rs508562, rs11675297, and haplotype 1 (OR, 1.41-2.34; p=0.004-0.05; OR, 1.74-1.82; p=0.03-0.05; OR, 0.42-0.67; p=0.0005-0.03, respectively) were significantly associated with clinical stage. Conclusions We conclude that there was no significant association between SRD5A2 SNPs and the risk of prostate cancer in the Korean population. However, we found that some SNPs and 1 haplotype influenced PSA level, Gleason score, and clinical stage.
Collapse
Affiliation(s)
- Se Young Choi
- Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea
| | - Hae Jong Kim
- Future Fusion Research Division, Korea Institute of Science and Technology, Department of Genetic Epidemiology, Seoul, Korea
| | | | - Soon Chul Myung
- Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea
| |
Collapse
|
14
|
Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, Danesi R. Genetic variation: effect on prostate cancer. BIOCHIMICA ET BIOPHYSICA ACTA 2014; 1846:446-56. [PMID: 25199985 PMCID: PMC4260983 DOI: 10.1016/j.bbcan.2014.08.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/17/2014] [Revised: 08/27/2014] [Accepted: 08/28/2014] [Indexed: 02/09/2023]
Abstract
The crucial role of androgens in the development of prostate cancer is well established. The aim of this review is to examine the role of constitutional (germline) and tumor-specific (somatic) polymorphisms within important regulatory genes of prostate cancer. These include genes encoding enzymes of the androgen biosynthetic pathway, the androgen receptor gene, genes that encode proteins of the signal transduction pathways that may have a role in disease progression and survival, and genes involved in prostate cancer angiogenesis. Characterization of deregulated pathways critical to cancer cell growth have lead to the development of new treatments, including the CYP17 inhibitor abiraterone and clinical trials using novel drugs that are ongoing or recently completed [1]. The pharmacogenetics of the drugs used to treat prostate cancer will also be addressed. This review will define how germline polymorphisms are known affect a multitude of pathways, and therefore phenotypes, in prostate cancer etiology, progression, and treatment.
Collapse
Affiliation(s)
- Tristan M Sissung
- National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Douglas K Price
- National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Marzia Del Re
- Department of Clinical and Experimental Medicine, University of Pisa, Italy
| | - Ariel M Ley
- National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Elisa Giovannetti
- Department of Clinical and Experimental Medicine, University of Pisa, Italy
| | - William D Figg
- National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Romano Danesi
- Department of Clinical and Experimental Medicine, University of Pisa, Italy
| |
Collapse
|
15
|
Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: a meta-analysis involving 18 studies. Tumour Biol 2014; 35:5921-30. [DOI: 10.1007/s13277-014-1785-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2014] [Accepted: 02/19/2014] [Indexed: 11/25/2022] Open
|
16
|
Jurečeková J, Sivoňová MK, Evinová A, Kliment J, Dobrota D. The association between estrogen receptor alpha polymorphisms and the risk of prostate cancer in Slovak population. Mol Cell Biochem 2013; 381:201-7. [PMID: 23737135 DOI: 10.1007/s11010-013-1703-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2013] [Accepted: 05/24/2013] [Indexed: 11/27/2022]
Abstract
The aim of our study was to evaluate the effect of two polymorphisms in the estrogen receptor alpha, PvuII and XbaI, on the development of prostate cancer within Slovak population, as well as their correlation with selected clinical characteristics. The study was performed using 311 prostate cancer patients and 256 healthy male controls. Both polymorphisms were significantly associated with higher risk of prostate cancer development. At the same time, the CC genotype of PvuII polymorphism (OR = 1.98; 95% CI 0.94-4.21; p = 0.05) and the AG genotype of XbaI polymorphism (OR = 1.74; 95% CI 1.0-3.02; p = 0.04) significantly contributed to the development of low-grade carcinoma, while the AG and GG genotypes of the XbaI polymorphism contributed mainly to the development of high-grade prostate cancer (OR = 1.83; 95% CI 1.12-3.01; p = 0.01 and OR = 2.13; 95% CI 1.06-4.19; p = 0.03, respectively). Similarly, the AG and GG genotypes of XbaI polymorphism showed significant association with prostate cancer in patients with serum PSA level ≥10 ng/ml. Both polymorphisms were found at the same time to be more frequent in patients diagnosed before the age of 60. We conclude on the basis of these results that PvuII and XbaI polymorphisms of estrogen receptor alpha might be associated with prostate cancer risk within Slovak population. Although this is a pilot study and, as such, more detailed investigations are needed to confirm the role of these polymorphisms in prostate cancer development and progression within said Slovak population, our results might still provide a valuable basis for further research with larger patient groups.
Collapse
Affiliation(s)
- Jana Jurečeková
- Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic.
| | | | | | | | | |
Collapse
|